ATAI Investor Presentation Deck

Our formulation & biomarker stratification companies provide an additional avenue of growth & innovation to the atai platform IntroSpect Digital therapeutics platform dedicated to improving patient outcomes through personalized care ■ Wholly owned platform company Introspect is focused on developing digital tools and devices in order to provide personalized clinical psychotherapy through the use of biomarkers IntroSpect's DTx is incorporated into clinical development plans for various atai pipeline products, including Viridia and Empath Bio EntheogeniX ■ ■ Al-enabled computational biophysics generating next generation of psychedelics- inspired mental health drugs Joint venture with Cyclica, a leading biotechnology company utilizing artificial intelligence and computational biophysics to streamline the drug discovery process Selecting for desirable pharmacological targets while avoiding undesirable anti-targets Cyclica's patented platforms allow researchers to visualize the complete polypharmacological profile of a compound InnarisBio Dedicated to developing a sol- gel based, intranasal excipient technology to facilitate nose- to-brain delivery of platform compounds Joint venture with UniQuest, the commercialization and technology transfer company of the University of Queensland, Australia InnarisBio uses a non- invasive, nose-to-brain delivery technology is designed to avoid systemic circulation and first-pass metabolism Potential advantages include increased patient compliance, ease of administration, and rapid onset of action IntelGenx ■ ■ An OTF manufacturer in Canada with a Canadian Schedule 1 license, allowing it to develop re-formulations of scheduled compounds 35 Strategic partnership with a minority ownership of 25% IntelGenx is developing an OTF formulation of Viridia's VLS-01, which is designed to enable delivery of therapeutics through oromucosal absorption Oromucosal absorption avoids the stomach and first-pass metabolism, therefore, allowing for non-invasive delivery of non-orally bioavailable therapeutics

View entire presentation